ArticleSubstance use & misuse2025
Geographical Differences in Self-Reported Past 12-Month Drug Use: Results from the NDEWS Rapid Street Reporting, 2021-2023.
Article in Substance use & misuse, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe National Drug Early Warning System Rapid Street Reporting study monitors over 100 drugs to identify emerging use trends.
objectivesThis analysis examined geographical differences in the past 12-month self-reported drug use across 20 US urban cities, identifying the three most prevalent drugs reported, excluding alcohol.
methodsAdults (age ≥18) were surveyed in public settings using venue-intercept sampling over a weekend in each city between January 2022 and November 2023 regarding past 12-month drug use. We focused on the three most commonly reported drugs in each region. The prevalence of reported drug use by region was compared using generalized linear models with Poisson and log-link functions, adjusting for participant characteristics, time of year, and location.
resultsAmong 6,039 participants, cannabis for recreational use (50.3%), psilocybin (13.7%), and cocaine (11.0%) were the most commonly reported drugs used. While there were no regional differences in the prevalence of recreational cannabis use, psilocybin, and cocaine use were more commonly reported by people in the West versus the Midwest (adjusted prevalence ratio [aPR]=1.58, 95% confidence interval [CI]: 1.23, 2.06; aPR=1.67, 95% CI: 1.26, 2.23, respectively). We also found a higher prevalence of cocaine use reported by participants in the Northeast compared to participants in the Midwest (aPR=1.37, 95% CI: 1.00, 1.91).
conclusionsVenue intercept survey method detected signals of recreational cannabis, psilocybin, and cocaine use in the 20 US urban cities visited over a weekend. Reported prevalence differed by region. This suggests that prevention messaging should be tailored to the specific US regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.